Stock Events

Sanofi 

$51.33
2620
+$0.12+0.23% Friday 20:00

Statistics

Day High
51.76
Day Low
51.21
52W High
53.45
52W Low
40.9
Volume
1,616,311
Avg. Volume
3,015,138
Mkt Cap
130B
P/E Ratio
21.57
Dividend Yield
3.97%
Dividend
2.04

Upcoming

Dividends

3.97%Dividend Yield
10Y Growth
0.65%
5Y Growth
3.41%
3Y Growth
1.83%
1Y Growth
7.2%

Earnings

25JulConfirmed
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Next
0.85
1.48
2.12
2.75
Expected EPS
0.85
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SNY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

55$Average Price Target
The highest estimate is $55.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Show more...
CEO
Paul Hudson
Employees
86088
Country
US
ISIN
US80105N1054
WKN
000662283

Listings